Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation of Revenue [Line Items]
Net sales	$ 2,695.9	$ 2,818.2	$ 5,284.1	$ 5,278.8
Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	424.1	442.8	851.4	832.8
Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	343.4	389.5	690.5	682.0
Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	492.2	436.3	955.9	826.4
Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	209.3	221.2	437.5	403.0
Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	291.9	292.8	539.5	532.3
Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	151.9	202.7	321.6	450.1
Dermatology
Disaggregation of Revenue [Line Items]
Net sales	106.5	126.8	233.7	222.7
Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	187.5	174.6	350.9	313.2
Oncology
Disaggregation of Revenue [Line Items]
Net sales	231.7	302.4	404.0	473.8
Immunology
Disaggregation of Revenue [Line Items]
Net sales	46.2	33.7	89.1	57.4
Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	211.2	195.4	410.0	485.1
North America Segment | Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	161.0	135.2	302.2	270.9
North America Segment | Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	38.3	30.5	83.4	48.6
North America Segment | Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	324.9	258.2	605.5	496.8
North America Segment | Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	59.8	48.9	125.9	95.8
North America Segment | Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	41.8	30.7	79.2	64.9
North America Segment | Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	51.5	83.8	116.6	234.8
North America Segment | Dermatology
Disaggregation of Revenue [Line Items]
Net sales	24.4	25.5	54.6	39.4
North America Segment | Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	95.5	90.2	179.9	169.1
North America Segment | Oncology
Disaggregation of Revenue [Line Items]
Net sales	170.3	246.9	299.4	371.7
North America Segment | Immunology
Disaggregation of Revenue [Line Items]
Net sales	9.9	9.0	19.0	19.1
North America Segment | Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	61.6	64.5	128.8	135.2
Europe Segment | Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	193.8	214.7	419.5	405.0
Europe Segment | Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	50.6	61.9	122.9	120.7
Europe Segment | Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	125.8	121.9	259.2	229.7
Europe Segment | Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	118.2	131.7	247.1	232.4
Europe Segment | Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	148.2	159.2	299.4	287.0
Europe Segment | Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	74.5	81.9	151.6	139.1
Europe Segment | Dermatology
Disaggregation of Revenue [Line Items]
Net sales	64.9	80.3	142.2	141.9
Europe Segment | Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	58.8	60.2	120.1	104.8
Europe Segment | Oncology
Disaggregation of Revenue [Line Items]
Net sales	22.2	20.3	40.8	37.9
Europe Segment | Immunology
Disaggregation of Revenue [Line Items]
Net sales	27.5	13.8	53.1	21.0
Europe Segment | Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	50.5	43.7	101.0	165.4
Rest of World Segment | Central Nervous System and Anesthesia
Disaggregation of Revenue [Line Items]
Net sales	69.3	92.9	129.7	156.9
Rest of World Segment | Infectious Disease
Disaggregation of Revenue [Line Items]
Net sales	254.5	297.1	484.2	512.7
Rest of World Segment | Respiratory & Allergy
Disaggregation of Revenue [Line Items]
Net sales	41.5	56.2	91.2	99.9
Rest of World Segment | Cardiovascular
Disaggregation of Revenue [Line Items]
Net sales	31.3	40.6	64.5	74.8
Rest of World Segment | Gastroenterology
Disaggregation of Revenue [Line Items]
Net sales	101.9	102.9	160.9	180.4
Rest of World Segment | Diabetes & Metabolism
Disaggregation of Revenue [Line Items]
Net sales	25.9	37.0	53.4	76.2
Rest of World Segment | Dermatology
Disaggregation of Revenue [Line Items]
Net sales	17.2	21.0	36.9	41.4
Rest of World Segment | Women's Healthcare
Disaggregation of Revenue [Line Items]
Net sales	33.2	24.2	50.9	39.3
Rest of World Segment | Oncology
Disaggregation of Revenue [Line Items]
Net sales	39.2	35.2	63.8	64.2
Rest of World Segment | Immunology
Disaggregation of Revenue [Line Items]
Net sales	8.8	10.9	17.0	17.3
Rest of World Segment | Other Therapeutic Franchises
Disaggregation of Revenue [Line Items]
Net sales	99.1	87.2	180.2	184.5
Operating Segment | North America Segment
Disaggregation of Revenue [Line Items]
Net sales	1,039.0	1,023.4	1,994.5	1,946.3
Operating Segment | Europe Segment
Disaggregation of Revenue [Line Items]
Net sales	935.0	989.6	1,956.9	1,884.9
Operating Segment | Rest of World Segment
Disaggregation of Revenue [Line Items]
Net sales	$ 721.9	$ 805.2	$ 1,332.7	$ 1,447.6